PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Catherine Uyttenhove, Luc Pilotte, Ivan Théate et al. · Nature Medicine · 2003 · 2.3K citations

Life Sciences, Cancer Biology, Immunology +11

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Medicine, Oncology, Urology +12

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +13

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

Kaoru Abiko, Noriomi Matsumura, Junzo Hamanishi et al. · British Journal of Cancer · 2015 · 709 citations · Full text

Medicine, Immunology, Oncology +17

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Simone Muenst, A. R. Schaerli, Feng Gao et al. · Breast Cancer Research and Treatment · 2014 · 578 citations · Full text

Medicine, Cancer Biology, Oncology +15